In adults with overweight or obesity, administration of weekly pemvidutide at doses up to 2.4 mg for 48 weeks is associated with minimal increases in heart rate and no clinically significant disruption of glycemic control as measured by glucose and HbA1c levels.

This medicine activates two receptors in the body: one that tells the brain to feel full and helps keep blood sugar steady, and another that makes the liver burn more fat for energy. The blood sugar stays stable because the first receptor helps the pancreas release just the right amount of insulin when needed, without overdoing it. The heart rate goes up only a little because the second receptor doesn’t strongly stimulate the heart, even though it boosts energy use elsewhere.